Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

NCT02520778 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

NIH

Sponsor class

Conditions

Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Stage III Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions

DRUG: Navitoclax
DRUG: Osimertinib

Sponsor

National Cancer Institute (NCI)